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Abstract 
Background: Coronary artery disease (CAD) evolving to acute myocardial infarction (AMI) is due to the 
thrombotic occlusion of coronary vessels in the presence of destabilized atheroma, rich in inflammatory cells 
secreting proteolytic enzymes that induce the development of thrombosis. The aim of this study was to analyse the 
plasma of AMI patients for the detection of proteases or factors that may cause fast coagulation. 
Methods: The patients were analysed for the presence in plasma of cardiac troponin T (c-TnT) or proteases 
as neutrophil gelatinase-associated lipocalin (NGAL) using ELISA method and matrix metalloproteinase-9 (MMP-9) 
utilising flow cytometry technique and interleukin-8 (IL-8) using flow cytometry methodology.
Results: The presence of AMI was demonstrated by high levels of c-TnT; in comparison with controls the AMI 
patients displayed a significant increase in the values of MMP-9 and low levels of antithrombin III: these markers 
were negatively correlated: MMP-9 appeared to cause the coagulation activity documented by the consumption of 
antithrombin III. The same patients also showed high levels of NGAL, which is known to modulate MMP-9 activity 
and to be involved in coagulation process: patients also exhibited an increased amount of IL-8 which appears to be 
associated with high levels of NGAL: this cytokine seems to affect the values of NGAL which is linked to coagulation 
process. 
Conclusion: The high levels of MMP-9, NGAL and IL-8 in AMI patients seemed to be interrelated and connected 
with the process leading to rapid coagulation. These markers may be measured in absence of AMI, particularly in 
CAD patients, as their detection may reveal a risk of sudden coronary coagulation.
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Introduction
Coronary artery disease (CAD) evolving to acute myocardial 
infarction (AMI) is associated with the thrombotic occlusion of coronary 
vessels in the presence of atheromatous plaque [1]. The atheroma is rich 
in inflammatory cells secreting proteolytic enzymes that may erode the 
fibrous cap and facilitate its rupture (unstable plaque) [2], and induce 
the development of coagulation and thrombosis [3].
It can be hypothesised that these secreted proteases such as matrix 
metalloproteinase-9 (MMP-9) [2], gelatinases such as neutrophil 
gelatinase-associated lipocalin (NGAL) [4], and cytokines such as IL-8 
[5] may be involved in the sudden coagulation process: their proteolytic 
activity may activate the development of thrombosis observed in acute 
myocardial infarction.
The aim of this study was to analyse the plasma of healthy subjects 
and AMI patients for the detection of proteases that may cause fast 
coagulation, in particular MMP-9, NGAL and the interleukin IL-8. 
Patients and Methods
Eight randomly selected male AMI patients aged 50-65 years 
and eight healthy male subjects of the same age were selected in 
order to verify whether these markers are interrelated in priming 
the coagulation and thrombosis that leads to AMI. This preliminary 
study was approved by the Ethical Committee of Niguarda Ca’ Granda 
Hospital Milan – Italy. 
The presence of AMI was demonstrated by measuring the specific 
marker c-TnT [6] and the plasma levels were evaluated using a 
commercial kit provided by Roche (Milan, Italy) [6].
MMP-9 and IL-8 were assayed using a BenderMed System flow 
cytomix simplex kits given by Prodotti Gianni (Milan, Italy), which 
were selected as representative examples of technologies currently used 
for high-throughput immunoanalysis [7]. NGAL was analysed using an 
enzyme-linked immunosorbent assay (ELISA) [8] supplied by Bioporto 
Diagnostic (Verona, Italy) in accordance with the manufacturer’s 
instructions. Plasma antithrombin III was measured using colorimetric 
method, based on a chromogenic substrate: S-2765:N-Z-D-ARG-GLY-
ARG-pNA using a kit provided by Instrumentation Laboratory (Milan, 
Italy) [9].
Statistical analysis
The values of the various biochemical markers, in the plasma of 
normal subjects and AMI patients, were compared using Kruskal-
Wallis test and the significance of differences (P) was calculated [10,11].
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The correlations between MMP-9 and antithrombin III or IL-8 
and NGAL were calculated using Spearman’s correlation coefficient 
[10,11].
Results
Table 1 shows the plasma values of c-TnT (ng/ml) observed in 
healthy subjects (<0.01) and AMI patients (3.20) with highly significant 
difference: P<0.001. c-TnT is a specific marker of AMI and clearly 
demonstrates the presence of AMI.
Table 1 reports the plasma values of MMP-9, antithrombin III, 
NGAL and IL-8 expressed as median and their significance calculated 
with Kruskal-Wallis test.
In particular the plasma levels of MMP-9 (ng/ml) observed 
in healthy subjects (29.25) and in AMI patients (32.35) exhibited 
significantly different values: P<0.034. The MMP-9 detected in plasma 
may affect biochemical process.
The levels of antithrombin III (mg/dl) found in healthy subjects 
(109.50) and AMI patients (96.00) appear to be significantly different: 
P<0.004.
The values of NGAL (ng/ml) detected in healthy subjects (67.00) 
and AMI patients (157.00) differ very significantly: P<0.004. The high 
increase of NGAL in AMI patients suggests a role of this marker in 
myocardial damage.
The values of IL-8 (pg/ml) observed in healthy subjects (13.82) and 
AMI patients (27.30) were significantly different: P<0.027. The increase 
of IL-8 suggests a role of this inflammatory marker in myocardial 
infarction.
The Spearman correlation between MMP-9 and antithrombin III 
appears to be significant (r=-0.523; P=0.05).
Discussion
The occurrence of AMI was demonstrated by high levels of the 
specific c-TnT marker [6] (Table 1). Remarkably, in the AMI patients, 
affected by acute coronary coagulation, were found, altered plasma 
values of MMP-9, antithrombin III, NGAL and IL-8. It appears to be 
quite important to analyse the links between these altered factors and 
the priming of coagulation. The AMI patients had higher MMP-9 levels 
than the controls. In addition, they had lower amount of antithrombin 
III, which is consumed by coagulation [12] and the lowering of 
antithrombin III during AMI or unstable angina was reported also by 
other authors [12,13]. Significant negative correlation between MMP-
9 and antithrombin III (r=-0.523; P=0.05; Spearman correlation) 
suggests that the former affected the levels of the latter and promoted 
coagulation. The process of coagulation is activated by MMP-9, which 
cleaves and inactivates tissue factor inhibitor and does not cleave 
tissue factor and factor VIIa [14]: thus MMP-9 allows the tissue factor 
to interact with factor VIIa: i.e. the clot starts with MMP-9 priming 
activity [15]. In addition it is known that the over-expression of MMP-
9 causes intravascular thrombus formation in porcine coronary artery 
[16].
Other authors also described high MMP-9 levels in cardiovascular 
diseases. MMP-9 was detected in 20% of the patients reported in 
the Framingham Heart Study [17]. The presence of this circulating 
biomarker reflects plaque inflammation, and its plasma concentration 
indicates the risk of future cardiovascular mortality in patients with 
CAD [18]. However, none of these studies [17,18] demonstrated that 
MMP-9 is directly involved in the coagulation process. 
The AMI patients had higher NGAL levels (Table 1). NGAL 
interacts with MMP-9, preserves it from degradation, and modulates 
its proteolytic activity [19], affecting coagulation [14,15]. It has been 
reported that NGAL levels are high in patients with CAD [20] and are 
related to the severity of the disease [8], and are increased in clinical 
and experimental heart failure [21]. However, although these findings 
suggest that NGAL may play an active pathophysiological role in the 
development of coronary events, none of them [8,20,21] demonstrate 
a direct relationship between NGAL and the priming of coagulation 
process. 
Finally, the AMI patients had high plasma IL-8 levels (Table 1); the 
same patients show high values of NGAL. It is important to remember 
that IL-8 exhibits the capacity to recruit the neutrophils [22] that 
releases NGAL [23], sorted to azurophil granules [24]. In addition, as 
IL-8 stimulates from human neutrophils [22] the release of NGAL [23] 
and MMP-9 [25,26] affecting coagulation [14,15], the IL-8 increase, 
observed, suggest that this factor may facilitate the coagulation 
process. High values of IL-8 or other chemokines can be used to predict 
cardiovascular risk [27], and indicate a probable future CAD in normal 
subjects [28,29]. However, none of these studies [27-29] demonstrate a 
connection between IL-8 and coagulation. 
As IL-8 stimulates from human neutrophils [22] the release of 
NGAL [23] and MMP-9 [25,26] affecting coagulation [14,15], the 
observed IL-8 increase suggests that this factor may be involved in 
facilitating the coagulation process.
Conclusions
In brief, we detected increased plasma MMP-9 in our AMI patients, 
who also had high levels of NGAL and IL-8. These markers appear to be 
interrelated and involved in the process leading to rapid coagulation: 
a clot starts with MMP-9 priming activity [14], which is modulated by 
NGAL [19] and affected by IL-8 [25,26]. Although it is also possible 
that the inflammatory cells found in the morphological changes that 
occur 12-24 hours after an AMI [1] may contribute to the release of 
factors affecting coagulation, the origin of the indicators here detected 
may be also attributed to inflammatory cells infiltrating atherosclerotic 
plaque [1-3,14].
We suggest that the markers MMP-9, NGAL and IL-8 found in 
AMI subjects and associated with sudden coagulation may be used in 
a large-scale study of CAD patients to reveal a risk of acute coronary 
syndrome.
Acknowledgements
This study is dedicated to the memory of Professor Cirillo Mussini (17.02.1936 
– 17.03.2007), the Founder and first President of the Concorde Group (Spezzano, 
Modena, Italy).
The authors are grateful to Doctor Luca Mussini, Managing Director to 
Concorde Group S.p.A. (Spezzano, Modena, Italy) for encouraging and funding 
this study.
cTnT 
 ng/ml
MMP-9  
ng/ml  
Antithrombin III  
mg/dl
NGAL
ng/ml
IL-8
pg/ml
Controls 0.01 29.25 109.50 67.00 13.82
AMI 3.20 32.35 96.00 157.00 27.30
Significance 
Kruskal-Wallis P<0.001 P<0.034 P<0.004 P<0.004 P<0.027
Table 1: Plasma markers detected in healthy subjects (controls) and acute 
myocardial infarction patients (AMI). Each value represents the median value of 
eight subjects. The significance P values calculated with Kruskal-Wallis test are 
reported.
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